Download presentation
Presentation is loading. Please wait.
Published byNeusa Escobar Modified over 5 years ago
1
DISCOVER OUR RANGE OF ELITE MONOCLONAL HYBRIDOMA CELL LINES & THEIR VALIDATED ANTIBODIES
2
Extensive customer base
Collaboration BioServUK – Sheffield, UK CMO Custom Antibody & Protein services Own the ELITE Hybridoma cell lines High manufacturing capacity Wider IVD client reach, further antibody validation Extensive customer base Diaserve Laboratories – Iffeldorf, Germany Clinical diagnostics IVD manufacturer Strong reputation amongst IVD customers
3
Target Market Marketplace Strategy Long-term Objective
Clinical Diagnostics Research Realise the market value from IVD customer validation Target early phase Drug Discovery Strategy Expand the ELITE Antibodies catalog Long-term Objective Provide the IVD and Research markets with high-quality antibodies to support advances in clinical diagnostics and improve healthcare
4
ELITE Antibodies Hybridoma cell lines licensed for RUO & IVD
Target a wide variety of research areas, focused on Fertility & Hormonal Control Highly validated for applications such as Flow Cytometry, ELISA & Immunofluorescence Hybridoma cell lines licensed for RUO & IVD
5
Antigen commercially available?
25 ELITE Antibodies Sandwich ELISAs Cat No. & Clone Description Applications Antigen commercially available? Disease areas PPG5/10 Mouse Anti-Estrogen Receptor β1, mAb, purified * WB, IHC, IF YES 57/3 Mouse Anti-Estrogen Receptor β2, mAb, purified * PPG5/25 Mouse Anti-Estrogen Receptor β5, mAb, purified * 17/2 Mouse Anti-Follistatin (FS288), mAb, purified * ELISA, WB, IHC, ICC H10 Mouse Anti-Follistatin (raised to FS315), mAb, purified * ELISA, WB, IHC 29/9 ELISA BetaC1 Mouse Anti-Activin C, mAb, purified * WB, IHC H4 Mouse Anti-CYP450 aromatase, mAb, purified * WB, IHC, IF, ICC MBP2 Mouse Anti-Myelin Basic Protein (region ), mAb, purified * ELISA, WB, IHC, IF, IP MBP1 Mouse Anti-Myelin Basic Protein (region ), mAb, purified * MBP12 Rat Anti-Myelin Basic Protein (region 82-87), mAb, purified * FC, ELISA, WB, IHC, IF, ICC MBP14 Rat Anti-Myelin Basic Protein (region 36-50), mAb, purified * ELISA, WB, IHC, IF, ICC MBP40 98/P12 Mouse Anti-Myelin Basic Protein (Thr98), mAb, purified * ELISA, WB, ICC DAZL3/11A Mouse Anti-Deleted in azoospermia-like, mAb, purified * 133 Mouse Anti-Protein Kinase C α, mAb, purified * PO12/8 Mouse Anti-Inhibin α, mAb, purified * ELISA, IHC PO 23/32 PLPC1 Mouse Anti-Proteolipid Protein, mAb, purified * FC, WB, IHC, IF, ICC 28A Mouse Anti-Growth Differentiation Factor 9B, mAb, purified * ELISA, WB, ICC, IB 53/1 Mouse Anti-Growth Differentiation Factor 9, mAb, purified * 72B Rat Anti- Growth Differentiation Factor 9, mAb, purified * ELISA, WB 32F8 Mouse Anti-Adiponectin, mAb, purified *, 399R Myo2/1A Mouse Anti-Myostatin, mAb, purified * WB, ICC Capture – 29/9 Detection – 17/2 Interchangeable Capture – 399R Detection – 32F8 * Also available as unpurified supernatant Endocrinology Cancer Fertility Immunology Neuroscience Haematology Hepatology Genetics Infectious Diseases Cardiology Diabetes Additional Research areas
6
Anti Inhibin α PO12/8
7
Anti Inhibin α PO12/8 Product Name Anti Human Inhibin α PO12/8 Catalogue Number PO12/8 Clone, Isotype PP12/8, IgG2a Format IgG Tested Applications ELISA, IHC All ELITE Antibodies are supplied as purified IgG Applications Suggested Dilution ELISA Assay dependent Immunohistochemistry 90 μg/ml
8
Anti Inhibin α PO12/8 Clone PO 12/8 used to stain prostate cancer cells and detect levels of inhibin α by IHC-P Image caption: Immunostaining in biopsy specimens from men with prostate cancer in regions of non-malignant (a, c, e) or malignant (b, d, f) tissue... Panels e and f show the up-regulation of inhibin α subunit immunoreactivity in malignant compared to non-malignant regions of tissue using the monoclonal antibody, PO#12. (Risbridger G.P et al.) Dilution used: 90 μg/ml Risbridger, G.P., Ball, E.M.A., Wang, E.M.A., Mellor, S.L., Peehl, D.M. (2004) Re-evaluation of inhibin α subunit as a tumour suppressor in prostate cancer. Molecular and Cellular Endocrinology, Volume 225, Issues 1–2, Pages 73-76, ISSN
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.